BioMarin Pharmaceutical | BMRN - 应收帐款人

金融业

USD

USD 8.59B

现金及等价物

USD 2.22B

USD 199.48M

USD 4.61B

USD 793.15M

USD 1.44B

USD 129.65M

USD 146.05M

3.04K

EPS每股收益

USD 0.76

股本和储备

USD 6.21B

USD 571.21M

债务利息支出

USD 14.96M

USD 22.56M

USD 1.43B

USD 9.76B

USD 105.53M

USD 636.56M

USD 129.65M

普通股股本

USD 193.27M

15.28

USD 141.2M

USD 766M

销售和管理费用

USD 258.28M

USD 1.27B

贸易债权人

USD 793.15M

应收帐款人

USD 903.91M

	应收帐款人	更改		日
Acadia Pharmaceuticals	USD 148.38M		153K	2026-03
Agios Pharmaceuticals	USD 16.13M		5.56M	2026-03
Alnylam Pharmaceuticals	USD 883.96M		106.39M	2026-03
Amgen	USD 9.14B		432M	2026-03
Bayer	EUR 18.55B		4.36B	2026-03
Biogen	USD 1.79B		76.6M	2026-03
BioMarin Pharmaceutical	USD 903.91M		4.3M	2026-03
Gilead Sciences	USD 4.74B		172M	2026-03
Incyte	USD 1.05B		27.09M	2026-03
Insmed	USD 178.55M		37.7M	2026-03
Ionis Pharmaceuticals	USD 74M		8M	2026-03
Moderna	USD 71M		113M	2026-03
Neurocrine Biosciences	USD 768.1M		81.3M	2026-03
PTC Therapeutics	USD 181.62M		21.45M	2025-12
Puma Biotechnology	USD 28.1M		3.52M	2024-06
Regeneron Pharmaceuticals	USD 5.73B		10.1M	2026-03
Roche Holding	CHF 11.9B		460M	2025-12
Sangamo BioSciences	USD 581K		110K	2024-06
Sanofi	EUR 397M		186.13M	2025-12
Sarepta Therapeutics	USD 547.91M		149.68M	2026-03
Ultragenyx Pharmaceutical	USD 60M		98M	2026-03
United Therapeutics	USD 312M		38.2M	2026-03
Vertex Pharmaceuticals	USD 2B		56.7M	2026-03